Literature DB >> 29444521

Non-Answered Questions in Patients with Endobronchial Valve Placement for Lung Volume Reduction.

Iván R Caviedes1, Gonzalo Labarca2,3, Hugo G de Oliveira4, Felix J F Herth5, Sebastián Fernandez-Bussy1.   

Abstract

Endoscopic lung volume reduction is a minimally invasive procedure performed to reduce the space occupied by the emphysemas' lobes. This procedure has been demonstrated to be beneficial for patients with advanced chronic obstructive pulmonary disease and severe hyperinflation. The use of endobronchial valves is increasing, as well as the number of reports of adverse events. The most common complications after the procedure are a pneumothorax, bleeding, infections, the need for valve removal, and valve expulsion. We have recently treated a patient who achieved immediate left upper lobe atelectasis but developed a pneumothorax on the 6th day and near-fatal kinking of the left lower lobe bronchus. This patient had asphyctic episodes probably due to a functional left pneumonectomy. We should consider this unusual complication in patients undergoing endoscopic lung volume reduction whose condition worsens after achieving complete lobar atelectasis.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Chronic obstructive pulmonary disease; Endoscopic lung volume reduction; Pneumothorax; Severe hyperinflation

Mesh:

Year:  2018        PMID: 29444521     DOI: 10.1159/000484252

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  1 in total

1.  Complications related to endoscopic lung volume reduction for emphysema with endobronchial valves: results of a multicenter study.

Authors:  Alfonso Fiorelli; Antonio D'Andrilli; Michela Bezzi; Mohsen Ibrahim; Marco Anile; Daniele Diso; Giacomo Cusumano; Alberto Terminella; Valentina Luzzi; Margherita Innocenti; Mauro Novali; Emanuele Carelli; Chiara Freda; Giovanni Natale; Valentina Peritore; Camilla Poggi; Giuseppe Failla; Marco Basile; Emilia Mazzucca; Serena Conforti; Nicola Serra; Massimo Torre; Federico Venuta; Erino Angelo Rendina; Mario Santini; Claudio Andreetti
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.